These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 11865966)

  • 1. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo.
    Timmer W; Leclerc V; Birraux G; Neuhäuser M; Hatzelmann A; Bethke T; Wurst W
    J Clin Pharmacol; 2002 Mar; 42(3):297-303. PubMed ID: 11865966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions.
    van Schalkwyk E; Strydom K; Williams Z; Venter L; Leichtl S; Schmid-Wirlitsch C; Bredenbröker D; Bardin PG
    J Allergy Clin Immunol; 2005 Aug; 116(2):292-8. PubMed ID: 16083782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis.
    Schmidt BM; Kusma M; Feuring M; Timmer WE; Neuhäuser M; Bethke T; Stuck BA; Hörmann K; Wehling M
    J Allergy Clin Immunol; 2001 Oct; 108(4):530-6. PubMed ID: 11590377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roflumilast: APTA 2217, B9302-107, BY 217, BYK 20869.
    Drugs R D; 2004; 5(3):176-81. PubMed ID: 15139782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
    Karish SB; Gagnon JM
    Ann Pharmacother; 2006 Jun; 40(6):1096-104. PubMed ID: 16735669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roflumilast: a selective phosphodiesterase 4 inhibitor.
    Christie P
    Drugs Today (Barc); 2005 Oct; 41(10):667-75. PubMed ID: 16389409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats.
    Chapman RW; House A; Jones H; Richard J; Celly C; Prelusky D; Ting P; Hunter JC; Lamca J; Phillips JE
    Eur J Pharmacol; 2007 Oct; 571(2-3):215-21. PubMed ID: 17610865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.
    Bundschuh DS; Eltze M; Barsig J; Wollin L; Hatzelmann A; Beume R
    J Pharmacol Exp Ther; 2001 Apr; 297(1):280-90. PubMed ID: 11259555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
    Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
    Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase 4 inhibition with roflumilast: a new approach to pulmonary disease.
    Doggrell SA
    Expert Opin Pharmacother; 2006 Mar; 7(4):485-8. PubMed ID: 16503820
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
    Hatzelmann A; Schudt C
    J Pharmacol Exp Ther; 2001 Apr; 297(1):267-79. PubMed ID: 11259554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of respiratory disease.
    Boswell-Smith V; Page CP
    Expert Opin Investig Drugs; 2006 Sep; 15(9):1105-13. PubMed ID: 16916276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roflumilast for asthma: Efficacy findings in mechanism of action studies.
    Bardin P; Kanniess F; Gauvreau G; Bredenbröker D; Rabe KF
    Pulm Pharmacol Ther; 2015 Dec; 35 Suppl():S4-10. PubMed ID: 26296794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors.
    Muise ES; Chute IC; Claveau D; Masson P; Boulet L; Tkalec L; Pon DJ; Girard Y; Frenette R; Mancini JA
    Biochem Pharmacol; 2002 Apr; 63(8):1527-35. PubMed ID: 11996895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
    Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
    Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roflumilast Altana Pharma.
    Reid P
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1165-70. PubMed ID: 12211409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Roflumilast for asthma and chronic obstructive pulmonary disease.
    Cowan C
    Issues Emerg Health Technol; 2005 Oct; (74):1-4. PubMed ID: 16317827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and potential anti-inflammatory activity of some tetrahydrophthalazinones.
    Gouault N; Pinel B; Cupif JF; Depince A; Martin-Chouly CA; Belleguic C; David M
    J Enzyme Inhib Med Chem; 2004 Dec; 19(6):475-80. PubMed ID: 15662951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.
    Lipworth BJ
    Lancet; 2005 Jan 8-14; 365(9454):167-75. PubMed ID: 15639300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.